NightHawk Biosciences Announces Completion Of Demonstration Run For A Top-Tier NIH And DTRA Funded Research University
Portfolio Pulse from Benzinga Newsdesk
NightHawk Biosciences (NYSE:NHWK) has successfully completed a demonstration run for a microbial vaccine program at its Scorpius BioManufacturing subsidiary, which is part of a multi-million-dollar project funded by NIH and DTRA for a top-tier research university. The next phase will involve scaling up cGMP manufacturing for a phase 1 trial targeting infectious disease. The company's CDMO services are in high demand due to a scarcity of large molecule manufacturing capacity.
December 21, 2023 | 1:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NightHawk Biosciences successfully completed a demonstration run for a vaccine program, moving to scale up cGMP manufacturing for a phase 1 trial, indicating progress in its CDMO services amid industry demand.
The successful completion of the demonstration run and the progression to the next phase of cGMP manufacturing for a phase 1 trial are significant positive developments for NightHawk Biosciences. This showcases the company's expertise and could potentially lead to increased revenues from its CDMO services. The demand for large molecule manufacturing capacity and the successful outperformance of a competitor further strengthen the positive outlook for NHWK in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100